Wedbush analyst Martin Fan raised the firm’s price target on Aclaris Therapeutics (ACRS) to $10 from $8 and keeps an Outperform rating on the shares. The firm notes the company reported updated pharmacokinetic/pharmacodynamic results for ATI-052 supporting every-three-months dosing, and announced plans to advance ATI-2138 development in lichen planus. Phase 1b trials in atopic dermatitis and asthma are underway, with a Phase 2 trial in asthma planned for Q4 2026, Wedbush adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial
- Aclaris Reports Positive ATI-052 Phase 1a Trial Results
- Aclaris Therapeutics management to meet virtually with Craig-Hallum
- 3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
- Aclaris Therapeutics initiated with an Outperform at Oppenheimer